Back at the end of last year, Endonovo kicked off a preclinical investigation assessing the Immunotronics platform in a target indication of myocardial infarction (or heart attack, as it’s more commonly known). The idea is to treat patients with the technology after they have suffered a first heart attack, with the goal of strengthening their cardiac muscle tissue and – in turn – reducing their chances of a second heart attack or complete heart failure (which is a remarkably common outcome in this patient population). At the trial’s initiation, the company reported that it expected to have data with shareholders by the end of the first quarter of this year. Fast forward a few months, and alongside a release detailing a fresh patent issue for the technology, management amended its target data release date to early second quarter 2017. The numbers haven’t hit press yet and we expect them to hit any day now. Why is this such a big deal? The implications of these numbers go beyond the myocardial infarction indication. The best way to look at his trial is as a sort of proof of concept study. If the company can prove that its technology has a regenerative impact on heart muscle tissue cells, there’s no real reason why it won’t have a similar impact on cells in other regions of the body.

Management just recently reported the initiation of two further preclinical studies, one in NASH and another in critical limb ischemia, and we see this as positive for the treatment’s chances of good MI data.

Why?

Well, it’s speculative, but why would a company kick off an expanded program if the proof of concept looked like it was failing? Chances are that management likes what it is seeing in the MI study and that it’s getting a jump on some expanded indications ahead of putting out the numbers.


1 Billion plus market cap on the horizon for ENDV.